Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Untere Zahlbacher Straße 8, D-55131, Mainz, Germany.
Center for Evidence-Based Psychiatry, Psychiatric Research Unit, Slagelse, Region Zealand Psychiatry, Denmark.
Curr Psychiatry Rep. 2020 Jun 5;22(8):37. doi: 10.1007/s11920-020-01164-1.
We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others. The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.
我们旨在确定最新的随机对照试验证据，评估诊断为 BPD 的患者继续药物治疗的效果，综述最新发现，关注当前正在进行的研究趋势，并对整体证据进行评论。
我们确定了 7 项新的 RCT，以及一项旧 RCT 的新可用数据。其中只有三项 RCT 已全文发表，而我们在试验注册平台上找到了其他 RCT 的研究数据。新发现不支持氟西汀作为预防自杀和自残的治疗选择。一项大型有效性研究未发现拉莫三嗪在常规护理中的有益效果。目前的证据并未反映或支持 BPD 中普遍使用的药物。需要更多的研究来评估最常用的物质和物质类别，即 SSRI 和喹硫平，以及针对具有明显合并症的人群。
